Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Apogee Therapeutics, Inc. Common Stock(APGE)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for APGE
09/03/2026: APGE (4-star) is a STRONG-BUY. BUY for 53 days. Simulated Profits (1.90%). Updated daily EoD!
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, long-acting biologic therapies for inflammatory diseases like atopic dermatitis and asthma. Its core strength lies in a specialized protein engineering platform that aims to improve treatment convenience and efficacy compared to existing standards. While the company's primary growth story is built on its promising pipeline of novel biologics, it operates in a high-risk sector facing intense competition from established pharmaceutical leaders. Investors should monitor clinical trial progress, as the company is currently pre-revenue and reliant on successful research outcomes to drive future valuation. Apogee is best suited for growth-oriented investors with a high tolerance for risk.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential linked to the potential success of its clinical-stage immunology pipeline. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may favor the stock during periods of positive clinical trial data or significant pipeline progress. |
| Value investor | Weak fit | As a loss-making clinical-stage biotech, Apogee does not currently offer the earnings or cash flow metrics sought by value investors. |
| Dividend investor | Weak fit | The company is in an aggressive growth phase and does not pay a dividend. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are inherently high-risk due to the possibility of trial failure. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to clinical trial announcements and broader biotech market sentiment. |
| Valuation risk | Medium / high | Valuations for pre-revenue biotech firms are highly speculative and depend heavily on future success probabilities. |
| Competition risk (immunology and biologics) | High | The company faces intense competition from global pharmaceutical leaders with massive scale and established market presence. |
| Business quality | Medium | The business relies on its proprietary engineering platform, which has yet to be validated by an FDA-approved commercial product. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | The ability to successfully navigate complex clinical trials and regulatory pathways is the primary determinant of long-term viability. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 169.32% | Avg. Invested days 43 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/03/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.22B USD | Price to earnings Ratio - | 1Y Target Price 134.62 |
Price to earnings Ratio - | 1Y Target Price 134.62 | ||
Volume (30-day avg) 1.1M shares | Beta 0.33 | 52 Weeks Range 35.39 - 135.09 | Updated Date 09/10/2026 |
52 Weeks Range 35.39 - 135.09 | Updated Date 09/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.34 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical-stage R&D | Development of novel protein-engineered monoclonal antibodies. | The company is currently burning cash to develop medicines; it will only earn revenue if these drugs receive regulatory approval and are sold to patients. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9.26B | Price to Sales(TTM) - |
Enterprise Value 9.26B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 62.20M | Shares Floating 58.44M |
Shares Outstanding 62.20M | Shares Floating 58.44M | ||
Percent Insiders 2.31 | Percent Institutions 110.8 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquarters San Francisco, CA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 261 | |
Full time employees 261 | |||
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.